OncoXome
North Hollywood, US · Founded 2021 · Delaware corporation · 1 known investors
Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.
Founders & leadership
AG
Auriane GamelinNamed on SEC filing
LG
Laurence GamelinNamed on SEC filing
EG
Erick GamelinNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$170.5K disclosed across 1 round · 2022
▶$170.5KraisedFeb 2023 · 2 investors · BiotechnologyRule 506(b)
▶$170.5KraisedFeb 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Auriane GamelinExecutive Officer, Director
- Laurence GamelinExecutive Officer, Director
- Erick GamelinExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $170.5K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapOncosenx3 shared keywordsOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Oncotelic Therapeutics3 shared keywordsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Companies competing with OncoXome for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does OncoXome do?
- Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.
- Who are OncoXome's investors?
- OncoXome's investors include The Innovation Space.
- How much funding has OncoXome raised?
- OncoXome has disclosed $170.5K raised across 1 round.
- Where is OncoXome headquartered?
- OncoXome is headquartered in North Hollywood, US.